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Objective:  The  serum  pregnancy-associated  plasma  protein-A  (PAPP-A)  concentration  is  a predictor  of
ischemic  cardiac  events  and  renal  impairment.  However,  the  reference  interval  of  PAPP-A has  not  been
determined.  This  study  determined  the  reference  interval  of  PAPP-A  in  men  and  non-pregnant  women.
Methods:  The  study  enrolled  126  apparently  healthy  individuals  (52 males  and  74 females).  The  mean
age  of  the  men  and  women  was  34.7  (range  20–66)  years  and  34.6  (range  18–65)  years,  respectively.
Serum  PAPP-A  concentrations  were  determined  using  an  ultrasensitive  enzyme-linked  immunoassay
kit.  Reference  intervals  were  calculated  using  the  bootstrap  method.
Results:  The  results  for  three  subjects  were  outliers,  so  the  reference  interval  of  PAPP-A was  calculated
using  the  data  for 123  subjects.  PAPP-A  was  undetectable  in  26  subjects.  The  reference  interval  of  PAPP-A
for men  and  women  (with  the  90%  conﬁdence  interval)  was  <22.9  ng/mL  (19.7–23.3)  and <33.6  ng/mLmoking (25.2–36.7),  respectively.  In  male  subjects,  serum  PAPP-A  levels  of  smokers  [3.10  (UD,  7.30)  ng/mL]  were
signiﬁcantly  lower  than  that of  non-smokers  [11.00  (UD,  24.4)  ng/mL]  (p  <  0.001)  and  there  was  a  positive
correlation  between  serum  PAPP-A  levels  and  subjects’  age  (r =  0.439;  p <  0.001).
Conclusions:  The  reference  interval  of  PAPP-A  differed  for men  and  non-pregnant  women.  In clinical
practice,  <22.9  ng/mL  for men  and  <33.6  ng/mL  for non-pregnant  women  may  be used as  reference
2  Jap
intervals  for  PAPP-A.
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Pregnancy-associated plasma protein-A (PAPP-A) is a member
f the insulin-like growth factor (IGF) axis [1].  This axis includes
rowth hormone (GH), IGF-1 and -2, six IGF-binding proteins
IGFBP-1–6), and IGFBP proteases. Normally, IGFs are bound to IGF-
Ps, which act as IGF carriers, but also modulate IGF availability and
ctivity [2].  PAPP-A is a protease (pappalysin-1, EC 3.4.24.79) of IGF-
Ps and its primary substrate is IGFBP-4, although it also cleaves
GFBP-2 and IGFBP-5 [1,3,4].  The proteolytic activity of PAPP-A
gainst IGBP-4 is IGF-dependent and it cleaves IGFBP-4 when it
s complexed with IGF. PAPP-A cleaves IGFBPs (IGFBP 2, 4, 5) and
ncreases the local concentrations of IGFs, which are involved in the
egulation of growth, proliferation, and differentiation of various
ell types.
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ttp://dx.doi.org/10.1016/j.jjcc.2012.09.007anese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
The serum mass concentrations of PAPP-A in the ﬁrst and
second trimesters are used to screen for genetic anomalies, par-
ticularly Down’s syndrome [5].  In addition to pregnancy, the
clinical value of PAPP-A, particularly in men  and non-pregnant
women, continues to grow as new data become available. PAPP-
A is potentially proatherosclerotic and high mass concentrations
have been reported in acute coronary syndromes (ACSs), asthma,
and renal impairment [6–9]. The serum PAPP-A mass concentra-
tion is an independent predictor of cardiac ischemia in patients
who present with suspected myocardial infarction, but remain
troponin-negative [10].
In ACS patients, elevated PAPP-A originates from atheroscle-
rotic plaques [11]. Bayes-Genis et al. used immunohistochemical
staining with antihuman PAPP-A antibodies and demonstrated that
PAPP-A was  abundantly expressed in the eroded and ruptured coro-
nary atherosclerotic plaques [9].  Additionally, they showed that
the cells that synthesize and secrete PAPP-A within the atheroscle-
rotic plaque are likely vascular endothelial and smooth muscle cells
[9].
Although great progress has been made in determining the
structure and function of PAPP-A, some variables need to be eval-
uated in clinical practice, including the reference interval and
vier Ltd. All rights reserved.
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Table 2
PAPP-A levels in study population.
Variables (n) Sub-variables (n) PAPP-A (ng/mL);
median (min., max.)
p
Male (50) 6.85 (UD, 24.40)
<0.011Female (73) 3.40 (UD, 36.70)
Male
Smoking (11) 3.10 (UD, 7.30)
<0.001Non-smoking 11.00 (UD, 24.40)
Female
Smoking (10) 3.00 (UD, 36.70)
<0.397Non-smoking 4.10 (UD, 36.70)
Pre-menopause 2.60 (UD, 36.70)
<0.137Post-menopause (13) 8.50 (UD, 21.60)A. Coskun et al. / Journal o
iagnostic sensitivity and speciﬁcity, particularly for cardiovascu-
ar events. Here, for the ﬁrst time, we investigated the reference
nterval of PAPP-A in men  and non-pregnant women.
aterials and methods
The study was conducted at the Acibadem Labmed Clinical Lab-
ratories, Istanbul, Turkey. The study protocol was approved by
he Ethics Committee of Acibadem University and all subjects gave
ritten informed consent before participating.
We  enrolled 126 apparently healthy individuals (52 men  and
4 women) to investigate the reference interval of PAPP-A. The
ean age of the men  and women was 34.7 (range 20–66) years
nd 34.6 (range 18–65) years, respectively. The subjects consid-
red themselves to be healthy and had no history of heart failure,
ypertension, hyperlipidemia, renal impairment, diabetes, major
rauma, or surgery. The characteristics of the study population are
hown in Table 1. No subjects were taking any prescribed drugs
r had been hospitalized recently. In addition, the female subjects
ere conﬁrmed to be not pregnant.
With the subjects in a sitting position, venous blood was col-
ected from an antecubital vein. Samples were transported to the
aboratory under identical conditions of temperature and elapsed
ime. After clotting, all samples were centrifuged at 1500 × g and
he serum was stored at −80 ◦C until analysis. At the end of the
tudy, all samples were analyzed on the same day in one run
sing a PAPP-A enzyme-linked immunoassay (ELISA) kit (ultrasen-
itive ELISA kit, DRG Instruments, Marburg, Germany). According
o the manufacturer, the within-run coefﬁcient of variation (CV)
as 6.86% and the detection limit of the method was  0.023 ng/mL.
tatistical analysis
We examined the data for outlying values visually and statisti-
ally. We  plotted the data distribution and then excluded outliers
hat were not part of the reference distribution. We  used the
olmogorov–Smirnov test to evaluate the normality of data. The
ann–Whitney U test was used to evaluate the signiﬁcance of
ifferences between serum PAPP-A levels of males and females,
moking and non-smoking subjects, and pre-menopause and post-
enopause women. Correlations between variables were assessed
sing Spearman correlation analysis. Values of p < 0.05 were con-
idered as statistically signiﬁcant.
To determine the presence of possible subclasses in the entire
ataset, we calculated the z and z-critical values, as recommended
y the Clinical and Laboratory Standards Institute (CLSI) [12].
inally, we used a non-parametric bootstrap approach to calculate
he reference interval of PAPP-A.
able 1
ubject characteristics.
Characteristics Female (n: 73) Male (n: 50)
Age, year, mean (range) 34.8 (18–65) 34.3 (20–66)
Menopause (n) 13
Body mass index, mean (range) 23.5 (18.2–38.9) 25.9 (19.9–34.4)
Smoking (n) 10 11
Hypertension – –
Diabetes – –
Hyperlipidemia – –
Heart failure – –
Renal impairment – –
Major trauma – –
Surgery within one year – –
Prescribed drugs – –
he pregnancy-associated plasma protein-A levels of three (two men  and one
oman) subjects were extreme values and so were removed from the study. Thus,
he  data of remaining 123 subjects were used.UD, undetectable.
Results
PAPP-A levels
As shown in Table 2, the median serum PAPP-A levels in
male subjects [6.85 (undetectable (UD), 24.40) ng/mL] were signif-
icantly higher than that of female subjects [3.40 (UD, 36.7) ng/mL]
(p < 0.011). In male subjects, serum PAPP-A levels were sig-
niﬁcantly lower in smokers [3.10 (UD, 7.30) ng/mL] than in
non-smokers [11.00 (UD, 24.4) ng/mL] (p < 0.001). Similarly, in
female subjects serum PAPP-A levels were lower in smok-
ers [3.00 (UD, 36.70) ng/mL] than in non-smokers [4.10 (UD,
36.70) ng/mL]. However, this difference was  not statistically signif-
icant (p > 0.05). Additionally, in female subjects the PAPP-A levels
in pre-menopause women [2.6 (UD, 36.7) ng/mL], were lower than
the post-menopause women  [8.5 (UD, 21.60) ng/mL], however this
difference was not statistically signiﬁcant, either (p > 0.05).
Correlation analysis
In male subjects, we found a statistically signiﬁcant correla-
tion between serum PAPP-A levels and subjects’ age (r = 0.439;
p < 0.001); however, in female subjects it was  not statistically signif-
icant (r = 0.103; p < 0.383). The correlation between serum PAPP-A
levels and body mass index (BMI) in both male and female subjects
was not statistically signiﬁcant (p > 0.05).Fig. 1. Serum pregnancy-associated plasma protein-A (PAPP-A) levels of all subjects
as  one group.
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littermates [25]. The role of PAPP-A in aging and age-related disease
needs to be investigated.
There are some limitations of the present study. In the litera-
ture different results of PAPP-A in various clinical situations have
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L)ig. 2. Serum pregnancy-associated plasma protein-A (PAPP-A) levels of women
nd  men  as separate groups.
eference intervals
Fig. 1 shows the serum PAPP-A levels of all 126 subjects. We  also
rew a graph to determine whether the data for men  and women
lustered separately (Fig. 2). As Figs. 1 and 2 show, the PAPP-A levels
f three (two men  and one woman) subjects were extreme val-
es and so were removed from the study. The z-value of the male
nd female groups (3.08) exceeded z-critical (2.16). Therefore, we
eparated the data for men  and women.
PAPP-A was not measurable in 5 men  and 21 women; conse-
uently we determined only the upper reference limit using the
onparametric bootstrap method. The calculated upper reference
imits and conﬁdence intervals for PAPP-A for men and women
ere 22.9 ng/mL (19.7–23.3) and 33.6 ng/mL (25.2–36.7), respec-
ively. Therefore, the PAPP-A reference intervals in men  and in
on-pregnant women are <22.9 ng/mL and <33.6 ng/mL, respec-
ively.
iscussion
Many papers on the relationship between PAPP-A and ACS have
een published [9–11], but a population-based reference inter-
al has not been determined. In this study, for the ﬁrst time, we
ave determined a population-based reference interval of PAPP-A
n men  and non-pregnant women.
Previously, we found that the index of individuality (II) of PAPP-
 was 0.95 [13]. If II < 0.48 for a test, the population-based reference
alues will be of little utility, while if II > 1.4, the population-based
eference values are signiﬁcant [14]. For PAPP-A, II = 0.95, meaning
hat the population-based reference values for PAPP-A have moder-
te utility. This means that partitioning may  be needed in reference
alue studies of PAPP-A. In this study, the z-values calculated for the
ata for men  and women were greater than z-critical. Accordingly,
hese results suggest that partitioning is necessary and that one
eference interval may  not be useful clinically for both men  and
omen.
This study included 126 subjects, which is adequate for non-
arametric calculation of the reference interval. Due to partitioning,
owever, each group had <120 subjects. Consequently, we  pre-
erred a bootstrap method over a non-parametric approach. In the
ootstrap method, a dataset is resampled randomly with replace-
ent, i.e. when an item is sampled it is replaced immediately,
ultiple times (as many as 1000–10,000 or more times) and
tatistical calculations, such as the reference and conﬁdence inter-
als in our study, are performed using this huge data collection
15]. The bootstrap method is preferred for reference intervaliology 61 (2013) 128–131
calculation when the number of subjects is <120. With few
subjects, it gives a more realistic conﬁdence interval than the non-
parametric approach.
The reference interval for men  was <22.9 ng/mL and for women
was <33.6 ng/mL. Interestingly, as shown in Table 2, the median
of serum PAPP-A levels in men  (6.85 ng/mL) was  higher than non-
pregnant women  (3.40 ng/mL) (p < 0.01). As shown in Fig. 2, despite
high median level, the dispersion of male data was  narrower than
female subjects and consequently the upper limit of women refer-
ence interval was  higher than men.
Various molecules such as pentraxin 3 [16], N-terminal pro-B-
type natriuretic peptide [17], urinary liver-type fatty acid binding
protein [18], and PAPP-A are being proposed as biomarkers for ACS.
However, high level of PAPP-A seems to be an independent risk
factor for cardiovascular event in patients with ACS [19]. Lobbes
et al. have studied 120 patients (87 males and 33 females) using
an ultrasensitive ELISA method (DRG) and found that PAPP-A is
elevated in acute myocardial infarction (25.5 ng/mL) and stable
(32.9 ng/mL) and unstable (52.9 ng/mL) angina pectoris. The data
in parenthesis are the mean differences of patient data from con-
trol group [20]. Heeschen et al. studied 644 patients with acute
chest pain. They found that elevated PAPP-A levels [>12.6 mIU/L
(56.7 ng/mL; 1 mIU  = 4.5 g)] indicated an increased risk for cardio-
vascular events [19]. In another study, Heider et al. found elevated
levels of PAPP-A in unstable versus stable plaques in patients
(0.10 ± 0.06 g/mL vs. 0.07 ± 0.04 g/mL; i.e. 100 ± 60 ng/mL vs.
70 ± 40 ng/mL) with carotid artery stenosis and correlation with
cap thickness [21]. Based on these ﬁndings, we suggest that our
reference interval data may  be used in clinical practice for healthy
men  and non-pregnant women.
In our study, we have shown that PAPP-A levels were lower
in smokers than in non-smokers. In pregnant women smoking is
associated with a reduction in birth size. It has been shown that
smoking during pregnancy decreases serum PAPP-A levels [22,23].
Smoking is a major risk factor for cardiovascular disease and the
high level of PAPP-A in cardiovascular events has been reported in
various papers. The inverse relation of smoking and PAPP-A needs
to be conﬁrmed in large population studies.
Another important ﬁnding of the present study is the posi-
tive correlation between age and PAPP-A levels in male subjects
(Fig. 3). Recent studies using genetically engineered mice indicate a
newly recognized role for PAPP-A in aging and in the development
of age-related disease [24]. Conover and co-workers have shown
that PAPP-A knock-out mice live 30–40% longer than wild-typeAge (Year)
Fig. 3. Correlation between serum pregnancy-associated plasma protein-A
(PAPP-A) levels and age in male subjects.
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een reported. The numerical value of PAPP-A is closely related to
he types of measurement method. Commonly ELISA, ultrasensitive
LISA, and electrochemiluminescence are used to determine serum
APP-A levels. Unfortunately, there has not been any standardiza-
ion among these methods, particularly for low PAPP-A levels in
en  and non-pregnant women. We  have used an ultrasensitive
LISA method (DRG). Thus, our reference interval should be inter-
reted accordingly. An interesting ﬁnding of this study is the low
evel of PAPP-A in smokers. The number of smokers in both male
nd female groups may  be adequate for statistical comparison, but
ot adequate for determination of reference intervals. For that rea-
on, the reference interval of PAPP-A in the smoking population
hould be determined separately.
Taken together, in the light of the literature we  conclude that
he upper reference limit of PAPP-A determined in our laboratory
<22.9 ng/mL for men  and <33.6 ng/mL for women), can be used in
linical practice, except in children and pregnant women.
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